Source: Annual Congress 2005 - COPD - treatment I
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Aubier, X. Duval, H. Knight, S. Perry, J. Wood, L. Brookman (Paris, France; Horsham, United Kingdom). Indacaterol, a novel 24-hour β₂-agonist, is effective and well tolerated on multiple dosing in patients with mild to moderate COPD. Eur Respir J 2005; 26: Suppl. 49, 1920

Member's Comments

No comment yet.

Related content which might interest you: Single-dose indacaterol, a novel 24-hour β2-agonist, is well tolerated in patients with mild asthma Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 Indacaterol, a novel once-daily β2-agonist, provides effective 24-hour bronchodilation in moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Indacaterol, a novel once-daily β2-agonist, is well tolerated in persistent asthma Source: Eur Respir J 2006; 28: Suppl. 50, 204s Year: 2006 Safety of multiple-dose indacaterol, a novel 24-hour β2-agonist, in moderate to severe COPD Source: Eur Respir J 2005; 26: Suppl. 49, 295s Year: 2005 Budesonide/formoterol in a single inhaler is well tolerated in patients with moderate to severe COPD: results of a 1-year study Source: Eur Respir J 2002; 20: Suppl. 38, 242s Year: 2002 NVA237 once daily provides rapid, clinically meaningful and sustained 24-h bronchodilation in patients with COPD: The GLOW1 trial Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 NVA237, a once-daily inhaled anticholinergic, provides 24-hour bronchodilator efficacy in patients with moderate-to-severe COPD Source: Eur Respir J 2006; 28: Suppl. 50, 527s Year: 2006 Indacaterol once-daily provides significant bronchodilation irrespective of baseline reversibility in COPD patients Source: Annual Congress 2010 - Bronchodilator treatment for asthma and COPD Year: 2010 Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Dual bronchodilation with QVA149 and the free combination of indacaterol and glycopyrronium are equally safe and well tolerated in patients with COPD: The BEACON study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 Indacaterol, a novel β2-agonist, demonstrates 24-hour efficacy and is well tolerated in patients with asthma: a multiple-dose, dose-ranging study Source: Eur Respir J 2005; 26: Suppl. 49, 253s Year: 2005 QVA149 once-daily is safe and well tolerated and improves lung function and health status in Japanese patients with COPD: The ARISE study Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs Year: 2013 The effects of adding in erdosteine on the routine bronchodilator therapy in moderate and severe COPD patients Source: Annual Congress 2006 - COPD therapy Year: 2006 Maintenance of bronchodilation following tiotropium in patients with mild, moderate and severe COPD in one year clinical trials Source: Eur Respir J 2001; 18: Suppl. 33, 331s Year: 2001 Efficacy of indacaterol is maintained in patients with moderate or less and severe or worse COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011 24-hour bronchodilator efficacy of single doses of indacaterol in patients with persistent asthma, and comparison with formoterol Source: Annual Congress 2008 - New treatments for asthma Year: 2008 Indacaterol once-daily is equally effective dosed either in the evening or morning in COPD patients Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009 Indacaterol once-daily provides effective 24-h bronchodilation in COPD patients: a 26-week evaluation vs placebo and tiotropium Source: Annual Congress 2009 - New bronchodilators Year: 2009 Budesonide/formoterol in a single inhaler is more effective than a higher dose of inhaled corticosteroids in patients with mild persistent asthma Source: Eur Respir J 2002; 20: Suppl. 38, 387s Year: 2002 Budesonide/formoterol in a single inhaler provides sustained improvements in lung function in patients with moderate to severe COPD Source: Eur Respir J 2002; 20: Suppl. 38, 397s Year: 2002